STAT

STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans

STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plansWorldPing

The FDA, while promising flexibility in approving Baby KJ-type gene editing, still has set standards difficult for a small startup to meet.

This is a short WorldPing brief. The full report was published by STAT.

Read the full report at STAT

Related news